Compare IMAX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | STOK |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | 2019 |
| Metric | IMAX | STOK |
|---|---|---|
| Price | $37.05 | $30.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $36.44 | $31.00 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 10-23-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.41 | N/A |
| EPS | ★ 0.71 | 0.68 |
| Revenue | ★ $377,677,000.00 | $205,632,000.00 |
| Revenue This Year | $17.45 | $416.54 |
| Revenue Next Year | $6.19 | N/A |
| P/E Ratio | $52.14 | ★ $45.14 |
| Revenue Growth | 9.30 | ★ 1128.17 |
| 52 Week Low | $20.48 | $5.35 |
| 52 Week High | $37.57 | $38.69 |
| Indicator | IMAX | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 69.08 | 60.05 |
| Support Level | $35.10 | $28.51 |
| Resistance Level | $37.21 | $29.38 |
| Average True Range (ATR) | 1.16 | 1.99 |
| MACD | 0.09 | 0.55 |
| Stochastic Oscillator | 84.20 | 93.67 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.